The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Camzyos



Bristol-Myers Squibb Pharma EEIGEU/1/23/1716/003-004/010

Main Information

Trade NameCamzyos
Active SubstancesMavacamten
Dosage FormCapsule, hard
Licence HolderBristol-Myers Squibb Pharma EEIG
Licence NumberEU/1/23/1716/003-004/010

Group Information

ATC CodeC01EB Other cardiac preparations
C01EB24 mavacamten

Status

License statusAuthorised
Licence Issued26/06/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back